EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence

Wirksamkeit und Sicherheit von Continuous Glucose Monitoring und intermittierend gescanntem Continuous Glucose Monitoring bei Patient:innen mit Typ-2-Diabetes: systematische Übersicht und Metaanalyse interventioneller Evidenz

Samuel Seidu iD, Setor K Kunutsor, Ramzi A Ajjan, Pratik Choudhary

Diabetes Care · 01.01.2024 · 47 (1) · 169-179

DOI: 10.2337/dc23-1520 ↗

Auf einen Blick

26 RCTs zeigen: CGM und isCGM senkten HbA1c bei Typ-2-Diabetes. isCGM erhöhte zudem die Anwenderzufriedenheit; beide Systeme waren mit mehr unerwünschten Ereignissen verbunden.

Fragestellung

Welche Vorteile und potenziellen Schäden haben CGM und isCGM im Vergleich zu üblicher Versorgung oder SMBG bei Typ-2-Diabetes?

Methode

Systematische Übersicht und Metaanalyse von RCTs; Suche in MEDLINE, Embase, Cochrane Library, Web of Science und Bibliografien bis August 2023.

Ergebnisse

26 RCTs mit 2.783 Patient:innen. CGM senkte HbA1c um −0,19 % (95 %-KI −0,34 bis −0,04) und das Medikations-Score um −0,67 (95 %-KI −1,20 bis −0,13). isCGM senkte HbA1c um −0,31 % (95 %-KI −0,46 bis −0,17).

Einschränkungen

Kleine Stichproben, Ergebnisse teils aus Einzelstudien, Populationen variabel; für die meisten Endpunkte <10 Studien; technologische Entwicklungen über die Zeit zu berücksichtigen.

Schlussfolgerung der Autor:innen

CGM und isCGM senkten bei Typ-2-Diabetes HbA1c. isCGM war zudem mit höherer Anwenderzufriedenheit verbunden; Auswirkungen auf Körperzusammensetzung, Blutdruck und Lipide bleiben unklar.

Kernaussagen

  • CGM: HbA1c −0,19 % (95 %-KI −0,34 bis −0,04)
  • isCGM: HbA1c −0,31 % (95 %-KI −0,46 bis −0,17)
  • Beide Systeme waren mit einem erhöhten Risiko unerwünschter Ereignisse verbunden

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift Diabetes Care, online erschienen am 20.12.2023. Verfasst von Samuel Seidu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Centre, National Institute for Health Research, Applied Research Collaboration East Midlands, University of Leicester, Leicester, U…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Ames Research Center NASA, NIHR Leicester Biomedical Research Centre, National Institute for Health Research.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Traditional diabetes self-monitoring of blood glucose (SMBG) involves inconvenient finger pricks. Continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems offer CGM, enhancing type 2 diabetes (T2D) management with convenient, comprehensive data. PURPOSE To assess the benefits and potential harms of CGM and isCGM compared with usual care or SMBG in individuals with T2D. DATA SOURCES We conducted a comprehensive search of MEDLINE, Embase, the Cochrane Library, Web of Science, and bibliographies up to August 2023. STUDY SELECTION We analyzed studies meeting these criteria: randomized controlled trials (RCT) with comparison of at least two interventions for ≥8 weeks in T2D patients, including CGM in real-time/retrospective mode, short-/long-term CGM, isCGM, and SMBG, reporting glycemic and relevant data. DATA EXTRACTION We used a standardized data collection form, extracting details including author, year, study design, baseline characteristics, intervention, and outcomes. DATA SYNTHESIS We included 26 RCTs (17 CGM and 9 isCGM) involving 2,783 patients with T2D (CGM 632 vs. usual care/SMBG 514 and isCGM 871 vs. usual care/SMBG 766). CGM reduced HbA1c (mean difference −0.19% [95% CI −0.34, −0.04]) and glycemic medication effect score (−0.67 [−1.20 to −0.13]), reduced user satisfaction (−0.54 [−0.98, −0.11]), and increased the risk of adverse events (relative risk [RR] 1.22 [95% CI 1.01, 1.47]). isCGM reduced HbA1c by −0.31% (−0.46, −0.17), increased user satisfaction (0.44 [0.29, 0.59]), improved CGM metrics, and increased the risk of adverse events (RR 1.30 [0.05, 1.62]). Neither CGM nor isCGM had a significant impact on body composition, blood pressure, or lipid levels. LIMITATIONS Limitations include small samples, single-study outcomes, population variations, and uncertainty for younger adults. Additionally, inclusion of <10 studies for most end points restricted comprehensive analysis, and technological advancements over time need to be considered. CONCLUSIONS Both CGM and isCGM demonstrated a reduction in HbA1c levels in individuals with T2D, and unlike CGM, isCGM use was associated with improved user satisfaction. The impact of these devices on body composition, blood pressure, and lipid levels remains unclear, while both CGM and isCGM use were associated with increased risk of adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2AdultHumansGlycated HemoglobinBlood GlucoseContinuous Glucose MonitoringBlood Glucose Self-MonitoringLipidsHypoglycemic Agents

Substanzen

Glycated HemoglobinBlood GlucoseLipidsHypoglycemic Agents

Autor:innen und Institutionen

  • Diabetes Research Centre, National Institute for Health Research, Applied Research Collaboration East Midlands, University of Leicester, Leicester, U.K.
  • Diabetes Research Centre, University of Leicester, National Institute for Health Research Biomedical Research Centre, Leicester General Hospital, Leicester, U.K.
  • Clinical Population and Sciences Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.

ORCID-Profile: Samuel Seidu

Förderung

  • Ames Research Center NASA
  • NIHR Leicester Biomedical Research Centre
  • National Institute for Health Research
  • Applied Research Collaboration East Midlands
  • ARC

Zitieren

APA

Seidu, S., Kunutsor, S. K., Ajjan, R. A., & Choudhary, P. (2024). Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence. Diabetes Care, 47(1), 169-179. https://doi.org/10.2337/dc23-1520

Vancouver

Seidu S, Kunutsor SK, Ajjan RA, Choudhary P. Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence. Diabetes Care. 2024;47(1):169-179. doi:10.2337/dc23-1520

BibTeX
@article{Seidu2024,
  author = {Seidu, Samuel and Kunutsor, Setor K and Ajjan, Ramzi A and Choudhary, Pratik},
  title = {Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence},
  journal = {Diabetes Care},
  year = {2024},
  volume = {47},
  number = {1},
  pages = {169--179},
  doi = {10.2337/dc23-1520}
}
Kostenlos starten →